PURPOSE Differentiating between prostate cancer (PC) lesions and benign structures which exhibit radiotracer uptake in PSMA-ligand PET/CT can be challenging. Additional late imaging has been shown to be a powerful method for the discrimination between PC and non-PC lesions, owing to the increasing tracer uptake of the former. Nevertheless, there are no pre-existing studies which describe the dynamic tracer uptake for ganglia, which this present study aims to address. METHODS Fifty consecutive patients with PC who received standard and late 68Ga-PSMA-11-PET/CT (by local protocol at 1.5 h "standard" and 2.5 h p.i. "late") underwent retrospective evaluation. All lesions with a tracer uptake above local background indicative for gangli...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
IntroductionProstate-specific membrane antigen (PSMA) is increasingly being recognized as a novel ta...
PURPOSE Dual-time point PET/CT scanning with [68Ga]Ga-PSMA-11 in the diagnosis of prostate cancer...
PURPOSE: Since the introduction of 68Ga-PSMA-11 PET/CT for imaging prostate cancer (PC) we have ...
Objective: Radiotracers targeting prostate-specific membrane antigen (PSMA) have increasingly been r...
Purpose To determine the frequency of seemingly pathological retroperitoneal uptake in the location ...
PURPOSE Since the introduction ofGa-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequ...
BackgroundThe recent implementation of PET with prostate specific membrane antigen (PSMA)-specific r...
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastas...
Radiolabelled prostate-specific membrane antigen (PSMA)-based PET–CT has been shown in numerous stud...
Purpose: Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imagi...
BACKGROUND: Recent studies reported metabolic uptake in at least one of the evaluated ganglia in 98....
IntroductionDynamic PET/CT allows visualization of pharmacokinetics over the time, in contrast to st...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
IntroductionProstate-specific membrane antigen (PSMA) is increasingly being recognized as a novel ta...
PURPOSE Dual-time point PET/CT scanning with [68Ga]Ga-PSMA-11 in the diagnosis of prostate cancer...
PURPOSE: Since the introduction of 68Ga-PSMA-11 PET/CT for imaging prostate cancer (PC) we have ...
Objective: Radiotracers targeting prostate-specific membrane antigen (PSMA) have increasingly been r...
Purpose To determine the frequency of seemingly pathological retroperitoneal uptake in the location ...
PURPOSE Since the introduction ofGa-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequ...
BackgroundThe recent implementation of PET with prostate specific membrane antigen (PSMA)-specific r...
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastas...
Radiolabelled prostate-specific membrane antigen (PSMA)-based PET–CT has been shown in numerous stud...
Purpose: Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imagi...
BACKGROUND: Recent studies reported metabolic uptake in at least one of the evaluated ganglia in 98....
IntroductionDynamic PET/CT allows visualization of pharmacokinetics over the time, in contrast to st...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
IntroductionProstate-specific membrane antigen (PSMA) is increasingly being recognized as a novel ta...